(Q33196127)

23 July 2017

1 reference

title

Diagnosis and treatment of carcinoid tumors (English)

1 reference

23 July 2017

1 reference

Kjell Oberg

1

1 reference

23 July 2017

publication date

1 December 2003

1 reference

Expert Review of Anticancer Therapy

23 July 2017

published in

1 reference

23 July 2017

volume

3

1 reference

23 July 2017

issue

6

1 reference

23 July 2017

page(s)

863-877

1 reference

Neuroendocrine tumors of the lung: recent developments in histopathology

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Recent advances in carcinoid pathogenesis, diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Diagnostic value of plasma chromogranin A in neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Neuroendocrine tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Carcinoid tumors: imaging procedures and interventional radiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Standardisation of imaging in neuroendocrine tumours: results of a European delphi process

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

The role of PET in localization of neuroendocrine and adrenocortical tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Transcatheter chemoembolization of progressive carcinoid liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Treatment of metastatic carcinoid tumour with recombinant interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Experience in treatment of metastatic pulmonary carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.6.863

21 January 2018

Identifiers

DOI

10.1586/14737140.3.6.863

1 reference

23 July 2017

1 reference